Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography

Gwenn Smith, Ma Yilong, Vijay Dhawan, Thomas Chaly, David Eidelberg

Research output: Contribution to journalArticle

Abstract

The effect of a pharmacologic increase in serotonin concentrations on striatal dopamine (D2) receptor availability has been measured in several studies using positron emission tomography (PET) and the radiotracer [ 11C]-raclopride as a method for the in vivo imaging of serotonin modulation of striatal dopamine in human subjects. These studies have shown that an acute increase in serotonin concentrations produced a decrease in striatal D2 receptor availability. The current study was undertaken to measure the effects of a more pharmacologically selective serotonergic agent compared to previous studies, the serotonin reuptake inhibitor, citalopram, on striatal D2 receptor availability. Twelve healthy control subjects underwent two PET scans performed on the same day following i.v. administration of saline (Scan 1) and citalopram (Scan 2, 40 mg, i.v.). The [11C]-raclopride data were analyzed with a graphical analysis method using the cerebellum as the input function. Plasma levels of citalopram, cortisol, and prolactin were measured. The citalopram concentrations peaked at the end of infusion (EOI) and remained relatively consistent from 30 min to 3 h postinfusion. An increase in cortisol and prolactin concentrations was observed from the EOI until 60 min after the EOI. A significant decrease in striatal D2 receptor availability was observed after citalopram infusion ( - 5%), presumably due to an increase in endogenous dopamine concentrations. In summary, i.v. administration of the selective serotonin reuptake inhibitor, citalopram, produced modest reductions in striatal D2 receptor availability, consistent with other human [11C]- raclopride studies using less pharmacologically selective serotonergic agents.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalSynapse
Volume63
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Raclopride
Corpus Striatum
Citalopram
Serotonin Uptake Inhibitors
Positron-Emission Tomography
Dopamine
Serotonin Agents
Serotonin
Prolactin
Hydrocortisone
Dopamine D2 Receptors
Cerebellum
Healthy Volunteers

Keywords

  • [C]-raclopride
  • Citalopram
  • Dopamine
  • Positron emission tomography (PET)
  • Selective serotonin reuptake inhibitors
  • Serotonin

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography. / Smith, Gwenn; Yilong, Ma; Dhawan, Vijay; Chaly, Thomas; Eidelberg, David.

In: Synapse, Vol. 63, No. 1, 01.2009, p. 1-6.

Research output: Contribution to journalArticle

Smith, Gwenn ; Yilong, Ma ; Dhawan, Vijay ; Chaly, Thomas ; Eidelberg, David. / Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography. In: Synapse. 2009 ; Vol. 63, No. 1. pp. 1-6.
@article{5e357e2ebfc240c2a26c0bf3d1499557,
title = "Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography",
abstract = "The effect of a pharmacologic increase in serotonin concentrations on striatal dopamine (D2) receptor availability has been measured in several studies using positron emission tomography (PET) and the radiotracer [ 11C]-raclopride as a method for the in vivo imaging of serotonin modulation of striatal dopamine in human subjects. These studies have shown that an acute increase in serotonin concentrations produced a decrease in striatal D2 receptor availability. The current study was undertaken to measure the effects of a more pharmacologically selective serotonergic agent compared to previous studies, the serotonin reuptake inhibitor, citalopram, on striatal D2 receptor availability. Twelve healthy control subjects underwent two PET scans performed on the same day following i.v. administration of saline (Scan 1) and citalopram (Scan 2, 40 mg, i.v.). The [11C]-raclopride data were analyzed with a graphical analysis method using the cerebellum as the input function. Plasma levels of citalopram, cortisol, and prolactin were measured. The citalopram concentrations peaked at the end of infusion (EOI) and remained relatively consistent from 30 min to 3 h postinfusion. An increase in cortisol and prolactin concentrations was observed from the EOI until 60 min after the EOI. A significant decrease in striatal D2 receptor availability was observed after citalopram infusion ( - 5{\%}), presumably due to an increase in endogenous dopamine concentrations. In summary, i.v. administration of the selective serotonin reuptake inhibitor, citalopram, produced modest reductions in striatal D2 receptor availability, consistent with other human [11C]- raclopride studies using less pharmacologically selective serotonergic agents.",
keywords = "[C]-raclopride, Citalopram, Dopamine, Positron emission tomography (PET), Selective serotonin reuptake inhibitors, Serotonin",
author = "Gwenn Smith and Ma Yilong and Vijay Dhawan and Thomas Chaly and David Eidelberg",
year = "2009",
month = "1",
doi = "10.1002/syn.20574",
language = "English (US)",
volume = "63",
pages = "1--6",
journal = "Synapse",
issn = "0887-4476",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography

AU - Smith, Gwenn

AU - Yilong, Ma

AU - Dhawan, Vijay

AU - Chaly, Thomas

AU - Eidelberg, David

PY - 2009/1

Y1 - 2009/1

N2 - The effect of a pharmacologic increase in serotonin concentrations on striatal dopamine (D2) receptor availability has been measured in several studies using positron emission tomography (PET) and the radiotracer [ 11C]-raclopride as a method for the in vivo imaging of serotonin modulation of striatal dopamine in human subjects. These studies have shown that an acute increase in serotonin concentrations produced a decrease in striatal D2 receptor availability. The current study was undertaken to measure the effects of a more pharmacologically selective serotonergic agent compared to previous studies, the serotonin reuptake inhibitor, citalopram, on striatal D2 receptor availability. Twelve healthy control subjects underwent two PET scans performed on the same day following i.v. administration of saline (Scan 1) and citalopram (Scan 2, 40 mg, i.v.). The [11C]-raclopride data were analyzed with a graphical analysis method using the cerebellum as the input function. Plasma levels of citalopram, cortisol, and prolactin were measured. The citalopram concentrations peaked at the end of infusion (EOI) and remained relatively consistent from 30 min to 3 h postinfusion. An increase in cortisol and prolactin concentrations was observed from the EOI until 60 min after the EOI. A significant decrease in striatal D2 receptor availability was observed after citalopram infusion ( - 5%), presumably due to an increase in endogenous dopamine concentrations. In summary, i.v. administration of the selective serotonin reuptake inhibitor, citalopram, produced modest reductions in striatal D2 receptor availability, consistent with other human [11C]- raclopride studies using less pharmacologically selective serotonergic agents.

AB - The effect of a pharmacologic increase in serotonin concentrations on striatal dopamine (D2) receptor availability has been measured in several studies using positron emission tomography (PET) and the radiotracer [ 11C]-raclopride as a method for the in vivo imaging of serotonin modulation of striatal dopamine in human subjects. These studies have shown that an acute increase in serotonin concentrations produced a decrease in striatal D2 receptor availability. The current study was undertaken to measure the effects of a more pharmacologically selective serotonergic agent compared to previous studies, the serotonin reuptake inhibitor, citalopram, on striatal D2 receptor availability. Twelve healthy control subjects underwent two PET scans performed on the same day following i.v. administration of saline (Scan 1) and citalopram (Scan 2, 40 mg, i.v.). The [11C]-raclopride data were analyzed with a graphical analysis method using the cerebellum as the input function. Plasma levels of citalopram, cortisol, and prolactin were measured. The citalopram concentrations peaked at the end of infusion (EOI) and remained relatively consistent from 30 min to 3 h postinfusion. An increase in cortisol and prolactin concentrations was observed from the EOI until 60 min after the EOI. A significant decrease in striatal D2 receptor availability was observed after citalopram infusion ( - 5%), presumably due to an increase in endogenous dopamine concentrations. In summary, i.v. administration of the selective serotonin reuptake inhibitor, citalopram, produced modest reductions in striatal D2 receptor availability, consistent with other human [11C]- raclopride studies using less pharmacologically selective serotonergic agents.

KW - [C]-raclopride

KW - Citalopram

KW - Dopamine

KW - Positron emission tomography (PET)

KW - Selective serotonin reuptake inhibitors

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=58149510607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149510607&partnerID=8YFLogxK

U2 - 10.1002/syn.20574

DO - 10.1002/syn.20574

M3 - Article

C2 - 18925655

AN - SCOPUS:58149510607

VL - 63

SP - 1

EP - 6

JO - Synapse

JF - Synapse

SN - 0887-4476

IS - 1

ER -